These innovative compounds represent a significant advancement in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://chiaracfzo072015.activoblog.com/47511319/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide